Navigation Links
Patient age not a factor in use of second-line therapy for lung cancer

Research published in the March issue of the Journal of Thoracic Oncology sought to determine whether differences existed in tolerance and efficacy between patients age 70 and over and younger patients with non-small cell lung cancer (NSCLC) receiving salvage targeted therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) or chemotherapy.

Lung cancer is the leading cause of cancer death in the world. Lung cancer incidence peaks between ages 70 and 80, and the mortality rate increases with age. EGFR-TKIs, such as gefitinib or erlotinib, are effective agents used in salvage therapy for NSCLC after patients have failed previous chemotherapy and have yielded a modest survival benefit. However, the majority of patients enrolled in these clinical trials using salvage therapy against NSCLC were younger than 70 years. Whether elderly patients are as suitable for salvage therapy as younger patients, and whether salvage targeted therapy is better or more tolerable than salvage chemotherapy in elderly patients are both unknown.

In this study, researchers retrospectively analyzed the data of 461 cases of nonelderly (under 70 years) and elderly (age 70 and older) patients with NSCLC who had failed previous chemotherapy and received salvage therapy. The treatment response rate, time to disease progression, overall survival time and toxicity profiles of the two groups were compared.

Elderly (>70 years)
Response Rate: 19%
Control Rate: 68%
Progression-free time: 4.4 months
Overall survival time: 9.3 months
One-year survival: 38%

Nonelderly (<70 years)
Response Rate: 24%
Control Rate: 68%
Progression-free time: 4.1 months
Overall survival time: 8.3 months
One-year survival: 41%

The nonelderly group had a similar response rate, control rate, and median survival time to the elderly group. In fact, the median progression-free time was numerically longer in the elderly than in the nonelderly patients. In addition, the use of EGFR-TKI salvage therapy, compared with salvage chemotherapies in the elderly group, resulted in a similar disease control rate and median survival time and more favorable toxicity profiles.

"In our study, we found there were no differences in the efficacy of salvage chemotherapies and EGFR-TKI therapy, in terms of response rate, control rate, and overall survival, in elderly and nonelderly patients, and the therapies had acceptable toxicities," said Chieh-Hung Wu, MD of Taipei Veterans General Hospital in Taiwan. "Age itself should not preclude patients with NSCLC from second-line salvage therapy with EGFR-TKIs. This is especially important as elderly patients are more easily frustrated when treatment for lung cancer fails and may refuse further salvage therapy."


Contact: Megan Richter
International Association for the Study of Lung Cancer

Related medicine news :

1. Lung cancer research explores the effects of patient attitudes on patient outcomes
2. Kidney Patients From Across South Carolina Visit State Capitol to Encourage Policies that Improve Patient Access to Life-Saving Dialysis and Transplant Care
3. Project Runways Tim Gunn Returns to Address Psoriasis(TM) and Empower Patients to be Confident in Their Personal Style
4. State payer mandates to cover cancer trials offer heterogeneous protection for patients
5. Death After Discharge Rates Higher in Elderly ICU Patients
6. New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association
7. The Right Colorectal Cancer Test for the Right Patient
8. Greenway Medical Technologies Advances Patient-Provider Benefits
9. Santa Rosa Consulting Announces New Free Education Series: Hot Topics in Patient Care Device Integration
10. Arizona Oncology Praises New Guidelines for Patient Care
11. Hospices not deactivating defibrillators in patients
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
(Date:10/12/2017)... ... 2017 , ... Vohra Chief Medical Officer Dr. Shark Bird, ... nursing facility medical directors and other clinicians at various events in October. His ... many of these conferences we get to educate other physicians, facility nurses, corporate ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... , Oct. 5, 2017  In response to ... Oral and Maxillofacial Surgeons (AAOMS) released prescribing recommendations ... to be used as a first-line therapy to ... Recognizing the value ... White Paper "Opioid Prescribing: Acute and Postoperative Pain ...
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:10/2/2017)... COPENHAGEN, Denmark , Oct. 2, 2017 The ... tool in the struggle to reverse the tide of prescription ... plan for regulating their medicine intake and stepping down their ... is set to launch in December 2017; the first 100,000 ... access. Learn more at ...
Breaking Medicine Technology: